Antisense Therapeutics Limited (AU:PER) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Percheron Therapeutics Limited has announced the World Health Organization’s selection of ‘avicursen’ as the proposed international nonproprietary name for its drug candidate ATL1102, aimed at treating rare diseases. The definitive confirmation of the INN is anticipated in May 2025, after which the company plans to adopt the new name. This milestone marks a significant step toward preparing ATL1102 for potential marketing authorization.
For further insights into AU:PER stock, check out TipRanks’ Stock Analysis page.